Xylazine-BSA Conjugate
| Code | Size | Price |
|---|
| LEI-X123-1mg | 1 mg | £536.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Lateral-Flow Immunochromatographic Assay
Shipping:
2 - 8°C Wet Ice
Storage:
This product is stable when stored at 2-8°C. Do not freeze.
Further Information
Concentration:
5.0 mg/mL
Conjugate/Tag/Label:
BSA
Format:
Formulated in 0.015 M phosphate buffered saline (0.15M NaCl) and contains 0.05% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
Formulated in 0.015 M phosphate buffered saline (0.15M NaCl) and contains 0.05% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Long Description:
Xylazine is a potent alpha-2 adrenergic agonist that was initially developed as a veterinary sedative and analgesic medication. Xylazine was not approved for human use and has been increasingly found in samples of illicit drugs like fentanyl. The increase in the detection of xylazine mixed with fentanyl has corresponded with an increase in overdose deaths. In 2023, fentanyl mixed with xylazine was declared an emerging threat by the White House?s Office of National Drug Control Policy.
Purity:
?90%
References
1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Link